Syncom Formulations (India) : Q4 2024 Financial Quarterly Report : YoY Sales Up 22.29 %, QoQ Up 14.48 %

The comprehensive analytics outlining the performance and outlook of Syncom Formulations (India) Limited”s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Syncom Formulations (India) Limited’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 22.29 %. However, it did see a marginal increase of 14.48 % from the previous quarter. Expenses ticked up slightly by 12.74 % quarter-on-quarter, aligning with the annual rise of 18.39 %. Operating profit, while up 58.22 % compared to last year, faced a quarter-on-quarter increase of 28.13 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.88 %, but an expansion of 1.35 % sequentially. Other income fell by -31.87 % compared to the last quarter, despite an annual decline of -54.21 %. Interest expenses surged remarkably by 11.11 % from the previous quarter, yet the year-over-year decrease remains at a moderate -6.98 %. Depreciation costs fell by -10.34 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 11.11 %. Profit before tax declined annually by -2.34 % but saw an increase from the preceding quarter by 6.93 %.
Tax expenses as a percentage of profits increased slightly by 8.58 % compared to last year, with a more notable quarter-on-quarter increase of 0.97 %. Net profit fell by -12.51 % year-on-year but experienced a 5.86 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 0 % but a quarterly rise of 11.11 %. In summary, Syncom Formulations (India) Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Syncom Formulations (India) Limited’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 22.29 % year-on-year growth, however, there was a minor increase of 14.48 % from the previous quarter. Expenses rose by 18.39 % compared to the previous year, with a 12.74 % increase quarter-on-quarter. Operating Profit surged by 58.22 % annually, and saw a 28.13 % increase from the last quarter.
Net Profit showed yearly decrease of -12.51 %, and experienced a 5.86 % increase from the previous quarter. Earnings Per Share (EPS) rose by 0 % annually, however rose by 11.11 % compared to the last quarter. In essence, while Syncom Formulations (India) Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.